Scotiabank Forecasts Strong Price Appreciation for Johnson & Johnson (NYSE:JNJ) Stock

Johnson & Johnson (NYSE:JNJ) had its target price increased by equities researchers at Scotiabank from $230.00 to $265.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “sector outperform” rating on the stock. Scotiabank’s target price indicates a potential upside of 20.60% from the stock’s previous close.

Other analysts have also issued research reports about the company. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. TD Cowen restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Guggenheim boosted their target price on shares of Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Raymond James Financial boosted their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Finally, Loop Capital set a $190.00 target price on Johnson & Johnson in a research report on Wednesday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $217.52.

Johnson & Johnson Stock Performance

Shares of JNJ traded up $1.73 during trading hours on Thursday, hitting $219.74. The stock had a trading volume of 2,997,707 shares, compared to its average volume of 9,212,171. The firm has a market capitalization of $529.41 billion, a price-to-earnings ratio of 21.22, a PEG ratio of 2.24 and a beta of 0.34. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $222.17. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a 50-day moving average price of $207.39 and a 200 day moving average price of $188.27.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, meeting analysts’ consensus estimates of $2.46. The company had revenue of $24.56 billion during the quarter, compared to the consensus estimate of $24.14 billion. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Johnson & Johnson’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.04 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Brighton Jones LLC grew its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. United Bank increased its stake in shares of Johnson & Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after purchasing an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC boosted its position in shares of Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock valued at $896,000 after acquiring an additional 692 shares during the period. Maseco LLP bought a new stake in Johnson & Johnson in the second quarter worth $478,000. Finally, Accurate Wealth Management LLC raised its stake in shares of Johnson & Johnson by 4.9% during the second quarter. Accurate Wealth Management LLC now owns 25,576 shares of the company’s stock valued at $4,033,000 after acquiring an additional 1,189 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q4 revenue beat and stronger outlook — J&J reported Q4 revenue of $24.56B (up 9.1% YoY) and issued FY‑2026 guidance that is modestly above Street forecasts, signaling continued top‑line momentum driven by oncology and MedTech. Read More.
• Positive Sentiment: Oncology and MedTech strength — cancer drugs (e.g., Darzalex) and MedTech growth powered the quarter; MedTech sales showed solid expansion, supporting sustainable revenue mix improvement. Read More.
• Positive Sentiment: New product and pipeline catalysts — submissions (OTTAVA robotic surgical system) and positive trial readouts create potential high‑growth levers beyond core drugs and devices. Read More.
• Neutral Sentiment: Guidance specifics — FY‑2026 EPS range of 11.430–11.630 and revenue ~$99.5–$100.5B were provided; they top consensus but incorporate expected pricing headwinds from a recent drug‑pricing agreement. Read More.
• Neutral Sentiment: Analyst activity and dividend story — some brokerages nudged targets higher (Stifel raised its target to $220 with a Hold rating) and J&J’s long dividend track record remains a structural support for the stock. Read More. • Read More.
• Negative Sentiment: Talc litigation progressing — a special master allowed plaintiffs to present expert testimony on general causation in the talc MDL, increasing legal uncertainty and potential liabilities. Read More.
• Negative Sentiment: Stelara biosimilar pressure — Stelara sales declined materially after patent loss and biosimilar competition, reducing a former revenue pillar and raising medium‑term growth risk. Read More.
• Negative Sentiment: Near‑term market reaction — despite the beat and raised guidance, shares pulled back (reported premarket/early declines) as investors rotated profits after strong 2025 gains and digested the legal/competitive headlines. Read More.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.